Clincosm LogoSign in Get a demo

immune checkpoint inhibitor

Showing 1 - 25 of 26
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model Trial in Beijing (Immune Checkpoint Inhibitors)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Immune Checkpoint Inhibitors
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Oct 5, 2023

Troponin to Detect Major Cardiovasculaire Advserse Events on

Recruiting
  • Cancer
  • +2 more
  • No intervention
  • Paris, France
    Institut Mutualiste Montsouris
Aug 22, 2023

Gastric Cancer, Chemo Effect, Immune Checkpoint Inhibitor Trial in Shanghai (Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU)

Recruiting
  • Gastric Cancer
  • +2 more
  • Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 1, 2023

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Intensity Modulated Radiation Therapy
  • +3 more
  • (no location specified)
Jul 11, 2023

Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Peking, Beijing, China
    Department of radiation oncology, Peking University Third Hospit
Jun 20, 2023

Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Recruiting
  • Graft Rejection
  • +3 more
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
Jun 21, 2023

Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Adjuvant tislelizumab plus lenvatinib
  • Adjuvant tislelizumab
  • Nanning, China
    Jian-Hong Zhong
Jun 11, 2023

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical

Recruiting
  • Cervical Cancer
  • +2 more
  • Treatment Group
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 9, 2023

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial (Liquid Biopsy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Liquid Biopsy
  • (no location specified)
Apr 18, 2023

Suspicion of Cardiovascular Events on Immunecheckpoint

Recruiting
  • Cancer
  • +3 more
  • No intervention for research purposes only
  • Paris, France
    Intitut Mutualiste Montsouris
Mar 23, 2023

Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy Trial in Chongqing (Super-hyperfractionation Pulse Radiotherapy)

Recruiting
  • Lung Cancer
  • +2 more
  • Super-hyperfractionation Pulse Radiotherapy
  • Chongqing, Chongqing, China
  • +1 more
Feb 22, 2023

Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
  • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
  • Jerusalem, Israel
    Shaare Zedek Medical Center
Jan 22, 2023

Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine

Completed
  • Immune Checkpoint Inhibitor
  • Endocrine Toxicity
    • Nanjing, Jiangsu, China
      First Affiliated Hospital, Nanjing Medical University
    Jan 6, 2023

    Immune Checkpoint Inhibitor, Lung Cancer, Liver Biomarkers Trial in Amiens (Blood sample)

    Recruiting
    • Immune Checkpoint Inhibitor
    • +3 more
    • Blood sample
    • Amiens, France
      CHU Amiens
    Dec 8, 2022

    Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

    Recruiting
    • Cancer
    • +2 more
      • Paris, France
        Institut Curie
      Nov 2, 2022

      Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora Trial in Guangzhou (RX-af01)

      Recruiting
      • Solid Tumor
      • +2 more
      • Guangzhou, Guangdong, China
        Miao-Zhen Qiu
      Oct 8, 2022

      Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin Trial in Hebei (Camrelizumab or envafolimab)

      Recruiting
      • Leptomeningeal Metastasis
      • +2 more
      • Camrelizumab or envafolimab
      • Hebei, China
        The Second Hospital of Hebei Medical University
      May 19, 2022

      Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor Trial in Beijing (Pembrolizumab)

      Recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • Beijing, China
        Peking Union Medical College Hospital
      May 17, 2022

      Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

      Recruiting
      • Cervical Carcinoma
      • +8 more
      • Camrelizumab plus Concurrent chemoradiotherapy
      • Beijing, Beijing, China
        Lei Li
      Apr 5, 2022

      Metastatic Colorectal Cancer, pMMR, MSS Trial in France (Atezolizumab, Therasphere, XELOX)

      Recruiting
      • Metastatic Colorectal Cancer
      • +4 more
      • Amiens, France
      • +18 more
      Mar 23, 2022

      Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation Trial in Shanghai (Toxicities reduced treatment arm)

      Recruiting
      • Oropharyngeal Carcinoma
      • +2 more
      • Toxicities reduced treatment arm
      • Shanghai, China
        Fudan Universtiy Shanghai Cancer Centre
      Apr 27, 2021

      Immune Checkpoint Inhibitors and Radiotherapy in

      Recruiting
      • Hodgkin Lymphoma
      • +2 more
      • Immune checkpoint inhibitor
      • Trieste, Italy
        SC Ematologia Ospedale Maggiore
      Sep 14, 2020

      Immune Checkpoint Inhibitor in NSCLC Patients

      Not yet recruiting
      • Adverse Reactions
      • +3 more
      • renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
      • (no location specified)
      Jul 15, 2020